GURUFOCUS.COM » STOCK LIST » USA » NYSE » Stryker Corp (NYSE:SYK) » Definitions » ROE %
Switch to:

Stryker (NYSE:SYK) ROE %

: 17.23% (As of Jun. 2023)
View and export this data going back to 1988. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Stryker's annualized net income for the quarter that ended in Jun. 2023 was $2,952 Mil. Stryker's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $17,128 Mil. Therefore, Stryker's annualized ROE % for the quarter that ended in Jun. 2023 was 17.23%.

The historical rank and industry rank for Stryker's ROE % or its related term are showing as below:

SYK' s ROE % Range Over the Past 10 Years
Min: 5.84   Med: 14.62   Max: 32.75
Current: 16.32

During the past 13 years, Stryker's highest ROE % was 32.75%. The lowest was 5.84%. And the median was 14.62%.

SYK's ROE % is ranked better than
87.08% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: -0.37 vs SYK: 16.32

Stryker ROE % Historical Data

The historical data trend for Stryker's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.75 16.98 12.35 14.26 14.97

Stryker Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.08 20.31 13.62 14.13 17.23

Competitive Comparison

For the Medical Devices subindustry, Stryker's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Stryker ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stryker's ROE % distribution charts can be found below:

* The bar in red indicates where Stryker's ROE % falls in comparison to its industry or sector. The grey bar indicates the ROE %'s extreme value range as defined by GuruFocus.



Stryker ROE % Calculation

Stryker's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=2358/( (14877+16616)/ 2 )
=2358/15746.5
=14.97 %

Stryker's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=2952/( (16895+17361)/ 2 )
=2952/17128
=17.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


Stryker  (NYSE:SYK) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=2952/17128
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2952 / 19984)*(19984 / 37119.5)*(37119.5 / 17128)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.77 %*0.5384*2.1672
=ROA %*Equity Multiplier
=7.95 %*2.1672
=17.23 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=2952/17128
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (2952 / 3596) * (3596 / 3872) * (3872 / 19984) * (19984 / 37119.5) * (37119.5 / 17128)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8209 * 0.9287 * 19.38 % * 0.5384 * 2.1672
=17.23 %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Stryker ROE % Related Terms

Thank you for viewing the detailed overview of Stryker's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stryker (NYSE:SYK) Business Description

Stryker logo
Address
2825 Airview Boulevard, Kalamazoo, MI, USA, 49002
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Executives
James Andrew Pierce officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Spencer S Stiles officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Skeete Tatum Lisa M director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher officer: VP, Chief Legal Officer 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Viju Menon officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Sherilyn S Mccoy director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Rajeev Suri director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary K Brainerd director 8170 33RD AVENUE SOUTH, BLOOMINGTON MN 55425
Graham A Mclean officer: President, Asia-Pacific 1 CORPORATE AVENUE ROWVILLE, VICTORIA C3 3178
Glenn S Boehnlein officer: Vice President, CFO 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink officer: VP, Global Human Resources 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Yin C Becker officer: VP, Comm. & Public Affairs 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Bijoy Sagar officer: VP, Chief Information Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Michael Damon Hutchinson officer: General Counsel 2825 AIRVIEW BLVD, KALAMAZOO MI 49002